PARMAR KUSH 4

What Happened

• Parmar Kush, reported as a 10% owner of Entrada Therapeutics (TRDA), was granted a derivative award on 2026-06-10 covering 19,000 shares. The award shows an acquisition at $0.00 (no cash paid) and is recorded as a derivative security (not an immediate share sale or open-market purchase).

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely filing).
• Award: 19,000 shares, acquisition price $0.00 (derivative grant, not exercised).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: the shares/options vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026, or (ii) the issuer's next annual meeting of stockholders.
• Transaction code: A = Award/Grant.

Context

• This was a grant of a derivative award (an option or similar instrument), meaning Kush did not immediately receive unrestricted shares or sell any shares; vesting/exercise conditions must be met before the underlying shares are acquired.
• As a 10% owner, this is a significant holder transaction (not necessarily routine executive trading). Grants to insiders are often compensation-related and don’t directly signal a buy/sell decision in the open market.